外周CD8⁺ T细胞克隆性与NK细胞扩增标志惰性B细胞淋巴瘤对mosunetuzumab的早期应答
本研究对接受固定疗程皮下mosunetuzumab治疗的初治滤泡性或边缘区淋巴瘤患者进行外周血免疫分析,发现治疗3周时出现广泛细胞因子诱导、CD8⁺ T细胞重分布及活化相关转录程序,治疗3个月时CD8⁺ T细胞克隆性增加且高克隆性与早期完全缓解相关,同时NK细胞间接活化扩增且CD56dimCD16bright效应状态偏移,中期NK细胞计数较高与完全缓解相关。
要点
- mosunetuzumab治疗早期诱导CD8⁺ T细胞活化、重分布及克隆扩增。
- 中期CD8⁺ T细胞克隆性增高与早期临床完全缓解相关。
- NK细胞间接活化扩增,中期NK细胞计数高与完全缓解相关。
核心结论
- mosunetuzumab治疗定义了一种CD8⁺效应重塑状态,特征为克隆扩增、选择性抑制性受体表达、胆固醇生物合成持续活化及细胞因子关联的先天免疫参与。
研究设计与样本
- 一项2期临床试验(NCT04792502)中接受固定疗程(6个月)皮下mosunetuzumab治疗的初治滤泡性或边缘区淋巴瘤患者的外周血样本免疫分析。
- 分析包括流式细胞术、细胞因子谱和分离CD8⁺ T细胞的RNA-seq及TCR库推断。
主要发现
- 治疗3周时出现广泛细胞因子诱导,CD8⁺ T细胞重分布伴TEMRA细胞减少和CD27⁺CD62L⁺过渡效应记忆样细胞增加,PD-1和LAG-3表达增加。
- CD8⁺转录程序与活化、增殖、耗竭启动及SREBF2调控的胆固醇代谢一致。
- 治疗3个月时活化相关特征向基线收缩,无表型耗竭证据,但RNA-seq显示LAG3、HAVCR2和LAYN持续过表达及SREBF2持续活化。
- 治疗中期CD8⁺ T细胞克隆性较基线增加,较高克隆性与早期临床完全缓解相关。
- mosunetuzumab诱导间接NK细胞活化和扩增,包括向CD56dimCD16bright效应状态偏移;NK细胞HLA-DR上调与NK活化血浆细胞因子早期增加相关,中期NK细胞计数较高与完全缓解相关。
临床怎么用
- 治疗早期外周CD8⁺ T细胞克隆性及中期NK细胞计数或可作为预测完全缓解的免疫标志物。
- 持续LAG3、HAVCR2、LAYN表达及SREBF2活化提示潜在支持T细胞功能的策略方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mosunetuzumab is highly effective against many B-cell lymphomas, but longitudinal immune changes induced by intermittently dosed CD20×CD3 bispecific antibodies remain incompletely characterized. We performed immune profiling of peripheral blood samples from patients receiving fixed-duration (6 months) subcutaneous mosunetuzumab for previously untreated follicular or marginal zone lymphoma on a phase 2 clinical trial (NCT04792502). Analyses included flow cytometry, cytokine profiling, and RNA-seq of isolated CD8+ T-cells with TCR repertoire inference. Early (at 3 weeks) on-treatment samples showed broad cytokine induction, CD8+ T-cell redistribution with decreased TEMRA cells and increased CD27+CD62L+ transitional effector memory-like cells, increased PD-1 and LAG-3 expression, and induction of CD8+ transcriptional programs consistent with activation, proliferation, exhaustion priming, and SREBF2-regulated cholesterol metabolism. By mid-treatment (at 3 months), activation-associated features contracted toward baseline, with no evidence of phenotypic exhaustion, though with persistent overexpression of LAG3, HAVCR2, and LAYN on RNA-seq, as well as sustained SREBF2 activation. CD8+ T-cell clonality increased at mid-treatment compared with baseline and higher clonality was associated with early clinical complete response. Mosunetuzumab also induced indirect NK-cell activation and expansion, including skewing toward CD56dimCD16bright effector state. HLA-DR upregulation on NK cells correlated with early increases in NK-activating plasma cytokines, and higher NK-cell count at mid-treatment was associated with complete response. Together, these findings define a CD8+ effector-remodeling state on mosunetuzumab therapy, characterized by clonal expansion, selective inhibitory receptor expression, sustained activation of cholesterol biosynthesis, and cytokine-linked engagement of innate immune mechanisms, providing a framework for potential strategies to support T-cell function and enhance bispecific antibody efficacy.
引用
- Milrod CJ, Chorzalska AD, Bonal DM, et al. Peripheral CD8⁺ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma. Blood Adv. 2026. PMID: 42721466. doi:10.1182/bloodadvances.2026021450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。